Anderson JL, Morrow DA. Acute myocardial infarction. N Engl J Med. 2017;376:2053–64.

Article  CAS  PubMed  Google Scholar 

Grüntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med. 1979;301:61–8.

Article  PubMed  Google Scholar 

McKavanagh P, Zawadowski G, Ahmed N, Kutryk M. The evolution of coronary stents. Expert Rev Cardiovasc Ther. 2018;16:219–28.

Article  CAS  PubMed  Google Scholar 

Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e18–114.

PubMed  Google Scholar 

2023 ESC Guidelines for the management of acute coronary syndromes | European Heart Journal | Oxford Academic. 2023. https://academic.oup.com/eurheartj/article/44/38/3720/7243210. Accessed 16 Oct 2023.

Jeger RV, Eccleshall S, Wan Ahmad WA, et al. Drug-coated balloons for coronary artery disease: third report of the International DCB Consensus Group. JACC Cardiovasc Interv. 2020;13:1391–402.

Article  PubMed  Google Scholar 

Madhavan MV, Kirtane AJ, Redfors B, et al. Stent-related adverse events >1 year after percutaneous coronary intervention. J Am Coll Cardiol. 2020;75:590–604.

Article  CAS  PubMed  Google Scholar 

Marlevi D, Edelman ER. Vascular lesion-specific drug delivery systems: JACC state-of-the-art review. J Am Coll Cardiol. 2021;77:2413–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation. 1989;79:733–43.

Article  CAS  PubMed  Google Scholar 

Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006;47:C13–18.

Article  CAS  PubMed  Google Scholar 

Arbab-Zadeh A, Fuster V. From detecting the vulnerable plaque to managing the vulnerable patient: JACC state-of-the-art review. J Am Coll Cardiol. 2019;74:1582–93.

Article  PubMed  Google Scholar 

Gaba P, Gersh BJ, Muller J, Narula J, Stone GW. Evolving concepts of the vulnerable atherosclerotic plaque and the vulnerable patient: implications for patient care and future research. Nat Rev Cardiol. 2023;20:181–96.

Article  PubMed  Google Scholar 

Dawson LP, Lum M, Nerleker N, Nicholls SJ, Layland J. Coronary atherosclerotic plaque regression: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79:66–82.

Article  PubMed  Google Scholar 

Libby P. Lipoprotein (a): a frustrating final frontier in lipid management? JACC Basic Transl Sci. 2016;1:428–31.

Article  PubMed  PubMed Central  Google Scholar 

Byrne RA, Joner M, Alfonso F, Kastrati A. Drug-coated balloon therapy in coronary and peripheral artery disease. Nat Rev Cardiol. 2014;11:13–23.

Article  CAS  PubMed  Google Scholar 

Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwälder U, Beregi J-P, Claussen CD, Oldenburg A, Scheller B, Speck U. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689–99.

Article  CAS  PubMed  Google Scholar 

Tzafriri AR, Muraj B, Garcia-Polite F, Salazar-Martín AG, Markham P, Zani B, Spognardi A, Albaghdadi M, Alston S, Edelman ER. Balloon-based drug coating delivery to the artery wall is dictated by coating micro-morphology and angioplasty pressure gradients. Biomaterials. 2020;260:120337.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cioppa A, Stabile E, Popusoi G, et al. Combined treatment of heavy calcified femoro-popliteal lesions using directional atherectomy and a paclitaxel coated balloon: one-year single centre clinical results. Cardiovasc Revasc Med. 2012;13:219–23.

Article  PubMed  Google Scholar 

Fanelli F, Cannavale A, Gazzetti M, Lucatelli P, Wlderk A, Cirelli C, d’Adamo A, Salvatori FM. Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease. Cardiovasc Intervent Radiol. 2014;37:898–907.

Article  CAS  PubMed  Google Scholar 

Myler RK, Shaw RE, Stertzer SH, Hecht HS, Ryan C, Rosenblum J, Cumberland DC, Murphy MC, Hansell HN, Hidalgo B. Lesion morphology and coronary angioplasty: current experience and analysis. J Am Coll Cardiol. 1992;19:1641–52.

Article  CAS  PubMed  Google Scholar 

Carrick D, Oldroyd KG, McEntegart M, et al. A randomized trial of deferred stenting versus immediate stenting to prevent no- or slow-reflow in acute st-segment elevation myocardial infarction (DEFER-STEMI). J Am Coll Cardiol. 2014;63:2088–98.

Article  PubMed  PubMed Central  Google Scholar 

Vos NS, Dirksen MT, Vink MA, van Nooijen FC, Amoroso G, Herrman J-PR, Kiemeneij F, Patterson MS, Slagboom T, van der Schaaf RJ. Safety and feasibility of a PAclitaxel-eluting balloon angioplasty in Primary Percutaneous coronary intervention in Amsterdam (PAPPA): one-year clinical outcome of a pilot study. EuroIntervention. 2014;10:584–90.

Article  PubMed  Google Scholar 

Belkacemi A, Agostoni P, Nathoe HM, et al. First results of the DEB-AMI (drug eluting balloon in acute ST-segment elevation myocardial infarction) trial: a multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in primary percutaneous coronary intervention with 6-month angiographic, intravascular, functional, and clinical outcomes. J Am Coll Cardiol. 2012;59:2327–37.

Article  PubMed  Google Scholar 

Garcia-Touchard A, Goicolea J, Sabaté M, et al. A randomised trial of paclitaxel-eluting balloon after bare metal stent implantation vs. bare metal stent in ST-elevation myocardial infarction (the PEBSI study). EuroIntervention. 2017;12(13):1587–94. https://doi.org/10.4244/EIJ-D-16-00128.

Article  PubMed  Google Scholar 

Gobić D, Tomulić V, Lulić D, Židan D, Brusich S, Jakljević T, Zaputović L. Drug-coated balloon versus drug-eluting stent in primary percutaneous coronary intervention: a feasibility study. Am J Med Sci. 2017;354:553–60.

Article  PubMed  Google Scholar 

• Vos NS, Fagel ND, Amoroso G, Herrman J-PR, Patterson MS, Piers LH, van der Schaaf RJ, Slagboom T, Vink MA. Paclitaxel-coated balloon angioplasty versus drug-eluting stent in acute myocardial infarction: the REVELATION randomized trial. JACC Cardiovasc Interv. 2019;12:1691–9. Findings of this study indicate that the DCB-only approach was not inferior to DES in terms of FFR, with no significant differences in terms of clinical outcomes at 9-month follow-up; therefore, the DCB-only approach appeared to be a safe and feasible strategy for treating STEMI patients.

Article  PubMed  Google Scholar 

Niehe SR, Vos NS, Van Der Schaaf RJ, Amoroso G, Herrman J-PR, Patterson MS, Slagboom T, Vink MA. Two-year clinical outcomes of the REVELATION study: sustained safety and feasibility of paclitaxel-coated balloon angioplasty versus drug-eluting stent in acute myocardial infarction. J Invasive Cardiol. 2022;34:E39–42.

PubMed  Google Scholar 

Hao X, Huang D, Wang Z, Zhang J, Liu H, Lu Y. Study on the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction. J Cardiothorac Surg. 2021;16:178.

Article  PubMed  Google Scholar 

Merinopoulos I, Gunawardena T, Corballis N, et al. Assessment of paclitaxel drug-coated balloon only angioplasty in STEMI. JACC Cardiovasc Interv. 2023;16:771–9.

Article  PubMed  Google Scholar 

Besic KM, Strozzi M, Margetic E, Bulum J, Kolaric B. Drug-eluting balloons in patients with non-ST elevation acute coronary syndrome. J Cardiol. 2015;65:203–7.

Article  PubMed  Google Scholar 

Scheller B, Ohlow M-A, Ewen S, et al. Bare metal or drug-eluting stent versus drug-coated balloon in non-ST-elevation myocardial infarction: the randomised PEPCAD NSTEMI trial. EuroIntervention. 2020;15:1527–33.

Article  PubMed  Google Scholar 

Mangner N, Farah A, Ohlow M-A, et al. Safety and efficacy of drug-coated balloons versus drug-eluting stents in acute coronary syndromes: a prespecified analysis of BASKET-SMALL 2. Circ Cardiovasc Interv. 2022;15:e011325.

Article  CAS  PubMed  Google Scholar 

Jeger RV, Farah A, Ohlow M-A, et al. Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. Lancet. 2020;396:1504–10.

Article  CAS  PubMed  Google Scholar 

•• Cortese B, Testa L, Heang TM, et al. Sirolimus-coated balloon in an all-comer population of coronary artery disease patients: the EASTBOURNE Prospective Registry. JACC Cardiovasc Interv. 2023;16:1794–803. Results of this large study suggest that sirolimus DCB is safe and feasible treatment approach for a wide range of coronary artery disease patients at midterm follow-up.

Article  PubMed  Google Scholar 

• Laricchia A, Bossi I, Latini RA, et al. Sirolimus-coated balloon in acute and chronic coronary syndromes: subanalysis of the EASTBOURNE registry. Rev Esp Cardiol (Engl Ed). 2023;S1885–5857(23):00336–5. For the first time, the findings of this study suggest sirolimus DCB performs well in terms of acute and 1-year outcomes in both ACS and CCS.

Google Scholar 

Shin E-S, Bang LH, Jun EJ, et al. Provisional drug-coated balloon treatment guided by physiology on de novo coronary lesion. Cardiol J. 2021;28:615–22.

Article  PubMed  PubMed Central  Google Scholar 

Rosenberg M, Waliszewski M, Chin K, et al. Prospective, large-scale multicenter trial for the use of drug-coated balloons in coronary lesions: the DCB-only All-Comers Registry. Catheter Cardiovasc Interv. 2019;93:181–8.

Article  PubMed  Google Scholar 

Jeger RV, Farah A, Ohlow M-A, et al. Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. Lancet. 2018;392:849–56.

Article  CAS  PubMed